Profile: UCB SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

61.00EUR
24 Nov 2014
Price Change (% chg)

€0.05 (+0.08%)
Prev Close
€60.95
Open
€61.05
Day's High
€61.51
Day's Low
€60.34
Volume
227,077
Avg. Vol
332,268
52-wk High
€75.62
52-wk Low
€48.17

Search Stocks
UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and in the area of immunology on allergies, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, UCB maintains UCB SA delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. UCB also has a selective presence in primary care to support specialist products that are administered by primary care physicians. In May 2013, it agreed to sell its production plant in Rochester, New York, to UNITHER Pharmaceuticals.

Company Address

UCB SA

Allee de la Recherche, 60
ANDERLECHT     1070
P: +322.5599999
F: +322.5599900

Search Stocks